Mirum Pharmaceuticals is making progress with a quartet of late-stage clinical trials designed to test brelovitug, the company’s experimental therapy for chronic hepatitis…
Hepatitis
Backed by millions in U.S. funding, scientists from Johns Hopkins Medicine in Baltimore will be leading a new international consortium working to find a cure…
A late-stage clinical trial assessing the safety and effectiveness of Mirum Pharmaceuticals’ brelovitug for adults with chronic hepatitis D has completed enrollment, and…
In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…
One-time treatment with VRON-0200 reduced hepatitis B virus (HBV) levels in the blood of most people with chronic hepatitis B — early trial findings…
Efforts to eliminate new hepatitis C cases by 2030, a goal set by the World Health Organization (WHO), are falling short in high-risk groups,…
A new test that uses a tiny drop of blood collected from a finger prick and returns results in about an hour can detect…
Dosing has begun in a Phase 1/2 clinical trial testing CRMA-1001, Nchroma Bio’s experimental epigenetic therapy being studied as a potential functional cure for…
Huahui Health‘s Libevitug has become the first approved treatment for chronic hepatitis D virus (HDV) infection in China. The country’s National Medical Products Administration…
After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly nine out of 10 evaluable…
Recent Posts
- Fearing liver cancer when you’re living with fatty liver disease
- Urine tests unreliable for pediatric cholestasis screening: Study
- Trial of WVE-007 for obesity aims to inform decisions about drug for MASH
- I’m grateful to make connections with the rare disease community
- Most babies with biliary atresia test positive for rotavirus antibodies